Cargando…
Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
Immunogenic cell death (ICD) has initially been discovered in the context of chemotherapy. High-dose crizotinib also stimulates ICD, as we described for non-small cell lung cancer lacking activating chromosomal aberrations of ALK or ROS1, the usual targets of crizotinib, indicating that crizotinib m...
Autores principales: | Petrazzuolo, Adriana, Perez-Lanzon, Maria, Liu, Peng, Maiuri, M. Chiara, Kroemer, Guido |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547833/ https://www.ncbi.nlm.nih.gov/pubmed/34712511 http://dx.doi.org/10.1080/2162402X.2021.1973197 |
Ejemplares similares
-
Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects
por: Petrazzuolo, Adriana, et al.
Publicado: (2021) -
Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer
por: Liu, Peng, et al.
Publicado: (2019) -
Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting
por: Kono, Koji, et al.
Publicado: (2013) -
Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade
por: Liu, Jiao, et al.
Publicado: (2022) -
Discovery of immunogenic cell death-inducing ruthenium-based photosensitizers for anticancer photodynamic therapy
por: Konda, Prathyusha, et al.
Publicado: (2020)